- Record: found
- Abstract: not found
- Article: not found
Application of 3D QSAR CoMFA/CoMSIA and in silico docking studies on novel renin inhibitors against cardiovascular diseases
Aggeliki Politi ,
Serdar Durdagi ,
Panagiota Moutevelis-Minakakis ,
George Kokotos ,
Manthos G. Papadopoulos ,
Thomas Mavromoustakos
September 2009
September 2009
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
For the first time, a set of renin inhibitors were subjected to the 3D QSAR/CoMFA
and CoMSIA studies. The utility of renin inhibitors in the treatment of cardiovascular
diseases has not been fully explored yet. At the moment, aliskiren is the first and
only existing renin inhibitor in the drug market. The performed 3D QSAR/CoMFA and
CoMSIA in combination with docking studies included aliskiren and 37 derivatives possessing
a wide variety of bioactivity. The obtained results may aid in the design of novel
bioactive renin inhibitors.